Sugi Predict

Sugi Predict / Compounds / SCHEMBL89565

SCHEMBL89565

SCHEMBL89565

CCOC[C@H](N)CC(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 5/20 0.44
▸ ERAP1 Q9NZ08 2/20 0.44
▸ ERAP2 Q6P179 1/20 0.44
▸ TSHR P16473 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ THPO P40225 1/20 0.42
▸ GMNN O75496 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ AAK1 Q2M2I8 3/20 0.37
▸ SLC7A5 Q01650 1/20 0.31
▸ LAP3 P28838 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9767570 1.00 ANPEP (0.44) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL9767580 1.00 ANPEP (0.44) ANPEPERAP1ERAP2TSHRCYP3A4
Hydrochloric Acid SCHEMBL56538 0.98 GMNN (0.44) ANPEPERAP1ERAP2TSHRCYP3A4
Hydrochloric Acid SCHEMBL56452 0.98 GMNN (0.44) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL9767573 0.87 ANPEP (0.50) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL5862306 0.82 ANPEP (0.46) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL913495 0.82 ANPEP (0.46) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL29322854 0.81 HSD17B10 (0.48) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL6215601 0.81 ALDH1A1 (0.32) ALDH1A1
SCHEMBL17152441 0.78 HTT (0.40) ANPEPERAP1ERAP2TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 — — US disclosed
CN-118647612-A Imidazolinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 珀哈制药公司 2024-09-13 — — CN disclosed
EP-4422747-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2024-09-04 — — EP disclosed
WO-2023072969-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
WO-2023072961-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
EP-4173673-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed
EP-4173674-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed
EP-2527338-B1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL) -3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2015-05-06 — — EP disclosed
EP-2181105-B1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2015-04-29 — — EP disclosed
US-8987456-B2 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 — — US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 — — EP disclosed
WO-2011013644-A1 SUBSTITUTED PIPERIDINE COMPOUND 第一三共株式会社 (JP) 2011-02-03 — — WO disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
WO-2009000811-A1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2008-12-31 — — WO disclosed
US-20080319018-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-12-25 — — US disclosed
US-20080319018-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-12-25 — — US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 ANPEP 819/4885ERAP1 959/4885ERAP2 1032/4885
US-20080319018-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 ANPEP 1719/4885ERAP1 2301/4885ERAP2 2035/4885
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 ANPEP 4585/4885ERAP1 2852/4885ERAP2 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.